PressJuly 7, 2023 PharmAla Biotech Holdings Inc. – Cortexa Makes First Drug Order for Australian Commercial Market
PressJuly 7, 2023 Revive Therapeutics Announces Results of Phase 3 Clinical Study for Bucillamine in the Treatment of COVID-19
PressJuly 7, 2023 COMPASS Pathways Secures Term Loan Facility for Up to $50 Million from Hercules Capital
PressJuly 7, 2023 Filament Health To Supply Psilocybin for Recipients of the Canadian Institutes of Health Research Psilocybin Operating Grants
PressJuly 5, 2023 Aion Therapeutic Announces Proposed Non-Brokered Private Placement Offering of Units
PressJuly 3, 2023 FSD Pharma Inc. Announces Results of Annual General and Special Meeting of Shareholders
PressJune 30, 2023 Filament Health Enters Exclusive Licensing Agreement With Neolumina Bioscience Inc.
PressJune 29, 2023 Reunion Neuroscience Reports Fiscal Fourth Quarter and Full Year 2023 Financial Results and Provides a Corporate Update
PressJune 29, 2023 Small Pharma Reports Financial Results for the Fiscal Year Ended February 28, 2023 and Recent Business Highlights
PressJune 27, 2023 PharmaTher Initiates Filing of Abbreviated New Drug Application for KETARX™ (racemic ketamine) to the FDA
PressJune 27, 2023 Algernon Pharmaceuticals Engages Maxim Group to Explore Spin-Off of its Ifenprodil Phase 2 Chronic Cough Drug Development Program
PressJune 27, 2023 Seelos Therapeutics Announces the Close of Enrollment of its Registration Directed Study of SLS-002 (Intranasal Racemic Ketamine) for Acute Suicidal Ideation and Behavior (ASIB) in Adults with Major Depressive Disorder (MDD)
